Scworx Announces Nasdaq Trading To Resume October 7, 2026
“We are pleased to resume trading on Nasdaq and bring this process to a successful conclusion,” said Tim Hannibal, President and Chief Executive Officer of SCWorx.“We appreciate the patience and continued support of our shareholders throughout this process. Our focus remains on executing our business strategy, expanding our customer relationships and creating long-term value for our shareholders.”
About SCWorx Corp.
SCWorx Corp. provides healthcare data management solutions designed to help healthcare organizations improve the accuracy, standardization and usability of their supply chain data. SCWorx combines healthcare-specific data expertise, proprietary data assets and technology-enabled workflows to enrich, normalize and manage healthcare product information used across supply chain, financial and clinical systems.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company's business strategy, growth opportunities, customer relationships and efforts to create long-term shareholder value. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information concerning risks and uncertainties affecting SCWorx is contained in the Company's filings with the Securities and Exchange Commission. SCWorx undertakes no obligation to update any forward-looking statement except as required by applicable law.
Investor Contact
SCWorx Investor Relations
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment